ScreenIT
The Automated Screening Working Groups is a group of software engineers and biologists passionate about improving scientific manuscripts on a large scale. Our members have created tools that check for common problems in scientific manuscripts, including information needed to improve transparency and reproducibility. We have combined our tools into a single pipeline, called ScreenIT. We're currently using our tools to screen COVID preprints.
Latest preprint reviews
-
Development and evaluation of low-volume tests to detect and characterise antibodies to SARS-CoV-2
This article has 47 authors:Reviewed by ScreenIT
-
SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa
This article has 43 authors:Reviewed by ScreenIT
-
Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
This article has 13 authors:Reviewed by ScreenIT
-
Change in stroke presentations during COVID-19 pandemic in South-Western Sydney
This article has 8 authors:Reviewed by ScreenIT
-
Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children
This article has 6 authors:Reviewed by ScreenIT
-
Socioeconomic inequality in SARS-CoV-2 testing and COVID-19 outcomes in UK Biobank over the first year of the pandemic: can inequalities be explained by selection bias?
This article has 9 authors:Reviewed by ScreenIT
-
Have infection control and prevention measures resulted in any adverse outcomes for care home and domiciliary care residents and staff?
This article has 12 authors:Reviewed by ScreenIT
-
Protection against omicron severe disease 0-7 months after BNT162b2 booster
This article has 10 authors:Reviewed by ScreenIT
-
What innovations can address inequalities experienced by women and girls due to the COVID-19 pandemic across the different areas of life/domains: work, health, living standards, personal security, participation and education?
This article has 12 authors:Reviewed by ScreenIT
-
Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial
This article has 20 authors:Reviewed by ScreenIT